Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14281289 | 0.75 | CES2 (0.39) | ALDH1A1MEN1KMT2ALMNAMAPT | |
| SCHEMBL21457582 | 0.72 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2APOLBLMNA | |
| SCHEMBL12715526 | 0.71 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2APOLBLMNA | |
| SCHEMBL12106077 | 0.71 | CES2 (0.52) | ALDH1A1MEN1KMT2APOLBLMNA | |
| SCHEMBL124653 | 0.69 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2APOLBLMNA | |
| SCHEMBL13908457 | 0.67 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2APOLBLMNA | |
| SCHEMBL3094764 | 0.66 | EGFR (0.52) | ALDH1A1MEN1KMT2APOLBLMNA | |
| SCHEMBL134312 | 0.66 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2APOLBLMNA | |
| SCHEMBL61242 | 0.65 | MEN1 (0.68) | ALDH1A1MEN1KMT2APOLBLMNA | |
| SCHEMBL9656417 | 0.63 | POLB (0.62) | ALDH1A1MEN1KMT2APOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059163-A1 | Non-linear opticaly active molecules, their synthesis, and use | OPTIMER PHOTONICS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20080004415-A1 | Non-linear optically active molecules, their synthesis, and use | OPTIMER PHOTONICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059163-A1 | Non-linear opticaly active molecules, their synthesis, and use | INCENP, CYBA, ADCY5 | ALDH1A1 371/4885MEN1 4480/4885KMT2A 3041/4885 |
| US-20080004415-A1 | Non-linear optically active molecules, their synthesis, and use | INCENP, CYBA, PAICS | ALDH1A1 378/4885MEN1 4473/4885KMT2A 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.